Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.
NCT00346827 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2019-07-10
Summary
To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.
Conditions
Interventions
- DRUG
-
Apomorphine Nasal Powder
Sponsors & Collaborators
-
Britannia Pharmaceuticals Ltd.
lead INDUSTRY
Principal Investigators
-
Richard Weiser, MB, MRCP · Swansea Hospital, Swansea, Wales
Study Design
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-07-31
- Primary Completion
- 2007-08-31
- Completion
- 2007-08-31
More Related Trials
-
Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease
NCT00200525 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
NCT02469090 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms
NCT00296192 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease
NCT00142545 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
NCT05979415 ·Status: TERMINATED ·Phase: PHASE2
-
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
NCT02688465 ·Status: TERMINATED ·Phase: PHASE4
-
Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)
NCT02864004 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Low Dose Apomorphine and Parkinsonism
NCT00472355 ·Status: WITHDRAWN ·Phase: PHASE2
-
Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease
NCT00806468 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
NCT04685265 ·Status: COMPLETED ·Phase: PHASE1
-
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
NCT02542696 ·Status: COMPLETED ·Phase: PHASE3
-
Apomorphine in Parkinson's Disease Patients With Visual Hallucinations
NCT02702076 ·Status: UNKNOWN ·Phase: PHASE2
-
Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug
NCT04810104 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes
NCT03292016 ·Status: COMPLETED ·Phase: PHASE2
-
OpiCapone Effect on Motor Fluctuations and pAiN
NCT04986982 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.
NCT03496870 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
NCT00986414 ·Status: COMPLETED ·Phase: PHASE2
-
Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease
NCT01683292 ·Status: COMPLETED ·Phase: PHASE2
-
PF 06412562 in Subjects With Advanced Stage Parkinson's Disease
NCT03665454 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Infusion of Apomorphine: Long-term Safety Study
NCT02339064 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease
NCT00240409 ·Status: COMPLETED ·Phase: PHASE3
-
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
NCT03187301 ·Status: COMPLETED ·Phase: PHASE2
-
Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease
NCT04887467 ·Status: COMPLETED ·Phase: PHASE4
-
An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease
NCT00918177 ·Status: COMPLETED ·Phase: PHASE2